Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?
dc.contributor.author | İnanç, Nevsun | |
dc.contributor.author | Özen, Gülşen | |
dc.contributor.author | Yalçınkaya, Yasemin | |
dc.contributor.author | Koca, Süleyman Serdar | |
dc.contributor.author | Can, Gerçek | |
dc.contributor.author | Karataş, Ahmet | |
dc.contributor.author | Yazıcı, Ayten | |
dc.contributor.author | Cefle, Ayşe | |
dc.contributor.author | Tufan, Abdurrahman | |
dc.contributor.author | Akar, Servet | |
dc.contributor.author | Şenel, Soner | |
dc.contributor.author | Öz, Burak | |
dc.contributor.author | Akkoç, Nurullah | |
dc.contributor.author | Önen, Fatoş | |
dc.contributor.buuauthor | Dalkılıç, Ediz | |
dc.contributor.buuauthor | Pehlivan, Yavuz | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Bilim Dalı. | tr_TR |
dc.contributor.researcherid | CMF-4757-2022 | tr_TR |
dc.contributor.researcherid | FQP-0451-2022 | tr_TR |
dc.date.accessioned | 2024-01-10T12:23:14Z | |
dc.date.available | 2024-01-10T12:23:14Z | |
dc.date.issued | 2018-06 | |
dc.description | Bu çalışma, 13-16, Haziran 2018 tarihlerinde Amsterdam[Hollanda]’da düzenlenen Congress of the European-League-Against-Rheumatism (EULAR) Kongresi‘nde bildiri olarak sunulmuştur. | tr_TR |
dc.description.sponsorship | European League Against Rheumatism | en_US |
dc.identifier.citation | İnanç, N. vd. (2018). ''Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?''. Annals of the Rheumatic Diseases, 77(Supplement 2), 611-612. | en_US |
dc.identifier.doi | https://doi.org/10.1136/annrheumdis-2018-eular.5662 | |
dc.identifier.eissn | 1468-2060 | |
dc.identifier.endpage | 612 | tr_TR |
dc.identifier.issn | 0003-4967 | |
dc.identifier.issue | Supplement 2 | en_US |
dc.identifier.startpage | 611 | tr_TR |
dc.identifier.uri | https://ard.bmj.com/content/77/Suppl_2/611.2 | |
dc.identifier.uri | https://hdl.handle.net/11452/38944 | |
dc.identifier.volume | 77 | tr_TR |
dc.identifier.wos | 000444351001597 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.wos | CPCIS | en_US |
dc.language.iso | en | en_US |
dc.publisher | BMJ Publishing Group | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.journal | Annals of the Rheumatic Diseases | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Rheumatology | en_US |
dc.subject.wos | Rheumatology | en_US |
dc.title | Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry? | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q1 (Rheumatology) | en_US |